Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
Iovance Biotherapeutics reported that Health Canada has approved its therapy Amtagvi (lifileucel) for patients with advanced melanoma who have already received anti-PD-1 and targeted therapies. This gives Canadian patients a new treatment option after other standard treatments have failed. The company shared this news through a press release, which is attached as an exhibit to the report.
Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics (IOVA), reported equity awards dated 08/06/2025. The Form 4 discloses a grant of 300,000 stock options with a $2.58 exercise price and an expiration date listed as 08/06/2035, and 150,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock. Both awards are held directly following the reported transactions. The awards vest only if the reporting person remains employed: one-third vests on the one-year anniversary of the grant and the remaining two-thirds vest in eight equal quarterly installments over the following two years. The form is signed by Corleen Roche on 08/08/2025.
Iovance Biotherapeutics (IOVA) filed an initial Form 3 reporting that Corleen Roche joined the company as Chief Financial Officer on 08/06/2025. The filing states that Ms. Roche does not beneficially own any securities of the issuer as of that date. The form is an initial statutory disclosure under Section 16 to record the reporting person's relationship and any ownership or derivative positions.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) filed a Form 8-K announcing the recruitment of Corleen Roche as Chief Financial Officer, effective August 6, 2025.
The Executive Employment Agreement, signed July 7, 2025, replaces current Principal Financial Officer Matthew W. Rosinack. Roche will receive an annual base salary of $600,000, a $50,000 one-time sign-on bonus, and is eligible for an annual discretionary bonus up to 45 % of salary.
Equity incentives under the 2018 Equity Incentive Plan comprise (i) an option to purchase 300,000 shares at the closing price on the effective date, vesting one-third after 12 months and quarterly thereafter, and (ii) 150,000 restricted stock units with identical vesting cadence. Unvested awards forfeit upon termination except where severance conditions are met.
Severance terms for a termination without cause include: (1) salary continuation for 12 months, (2) pro-rated bonus, (3) immediate vesting of unvested equity, and (4) continuation of applicable benefits. Enhanced protection applies upon a change-of-control event.
Professional background: Roche, 59, has served as CFO of CG Oncology (2024-present), Immunome (2021-2023), and Biogen U.S. (2019-2021), following senior finance roles at Sandoz and Wyeth. She began her career at PwC and holds a B.A. in Accountancy from Villanova University.
The Company issued a press release (Exhibit 99.1) on July 15, 2025 to publicly announce the appointment.